Search filters

List of works by Jacob P Laubach

A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma

scientific article published on 31 October 2019

A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results.

scientific article

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma

scientific article published on 08 May 2018

A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma

scientific article

A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.

scientific article published on 3 May 2017

Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1

scientific article published on 12 March 2018

Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy

scientific article published on 23 June 2014

Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group

scientific article published on 06 March 2019

Bortezomib in the management of multiple myeloma ⬇️

scientific article published on September 8, 2009

Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia

scientific article

Clinical translation in multiple myeloma: from bench to bedside

scientific article published on October 2013

Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function

scientific article

Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia

scientific article published in February 2010

Conflicts of interest, authorship, and disclosures in industry-related scientific publications

scientific article

Daratumumab granted breakthrough drug status

scientific article published on 20 February 2014

Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations

scientific article published on June 2015

Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?

scientific article

Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study

scientific article published on 29 May 2018

Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib

scientific article published on April 2009

Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study

scientific article published on 31 March 2019

Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma.

scientific article published on 11 April 2011

Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression

scientific article published on 22 May 2020

Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing

scientific article published on 27 March 2018

Hematology: Thalidomide maintenance in multiple myeloma

scientific article published in October 2009

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results.

scientific article published on 13 February 2018

IgD and IgE variants of myeloma: valuable insights and therapeutic opportunities.

scientific article

IgM myeloma: A multicenter retrospective study of 134 patients

scientific article published on 6 April 2017

Imaging Features of Extramedullary, Relapsed, and Refractory Multiple Myeloma involving the Liver Across Treatment With Cyclophosphamide, Lenalidomide, Bortezomib, and Dexamethasone ⬇️

scientific article published on June 11, 2012

Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma.

scientific article published on 07 June 2017

Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers ⬇️

scientific article published on January 10, 2011

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

scientific article published on 09 November 2018

Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma

scientific article published on 10 May 2018

Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies

scientific article published on 08 May 2019

Latest advances and current challenges in the treatment of multiple myeloma ⬇️

scientific article published on February 21, 2012

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma

scientific article published on 15 May 2015

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy ⬇️

scientific article published on June 15, 2010

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications

scientific article

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial

scientific article

MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias

scientific article published on June 1, 2011

Management of Relapsed and Relapsed/Refractory Multiple Myeloma ⬇️

scientific article published on 01 October 2011

Management of myeloma-associated renal dysfunction in the era of novel therapies

scientific article published on February 2012

Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings ⬇️

scientific article published on 07 July 2011

Maximizing the clinical benefit of novel therapies in multiple myeloma

scientific article published on April 2009

Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells

scientific article published on 13 September 2012

Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications

scientific article

Multiple myeloma

scientific article published on 01 January 2011

New proteasome inhibitors in myeloma

scientific article published on December 2012

Novel targeted agents in the treatment of multiple myeloma

scientific article published on 05 August 2014

Novel therapies in the treatment of multiple myeloma

scientific article published on October 2009

Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide

scientific article

Panobinostat for the Treatment of Multiple Myeloma.

scientific article published on 11 September 2015

Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma

scientific article published on 07 June 2015

Pathological crystallization of human immunoglobulins ⬇️

scientific article published on July 30, 2012

Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial ⬇️

scientific article published on October 11, 2011

Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy

scientific article published on January 2013

Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1

scientific article

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib ⬇️

scientific article published on December 14, 2012

Phase transitions in human IgG solutions

scientific article

Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma

scientific article

Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma.

scientific article published on 19 October 2017

Setting the standard for newly diagnosed multiple myeloma ⬇️

scientific article published on March 22, 2011

Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in <i>BRAF</i>-Mutated Multiple Myeloma

scientific article published on 13 September 2021

Tailoring treatment for multiple myeloma patients with relapsed and refractory disease

scientific article published in March 2010

Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma ⬇️

scientific article published on February 1, 2011

The Medical Research Council Myeloma IX trial: the impact on treatment paradigms* ⬇️

scientific article published on November 22, 2011

The challenge of cross-trial comparisons using limited data

scientific article published on August 2014

The evolution and impact of therapy in multiple myeloma

scientific article published on 19 February 2010

The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease

scientific article published on 01 August 2018

The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.

scientific article published on January 2015

The potential benefits of participating in early‐phase clinical trials in multiple myeloma: long‐term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib ⬇️

scientific article published on 07 March 2012

The power of proteasome inhibition in multiple myeloma

scientific article published on 14 November 2018

The treatment of multiple myeloma patients not eligible for asct ⬇️

scientific article published on May 3, 2010

Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans ⬇️

scientific article published on January 15, 2013

Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients ⬇️

scientific article published on May 17, 2013

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study

scientific article

Paulina is supported by:

About Paulina

Help